COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 08/03/23
COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023GlobeNewsWire • 07/31/23
This Unexpected Development Is Yet Another Green Flag for Compass Pathways StockThe Motley Fool • 07/28/23
First clinical study results of psilocybin treatment in anorexia nervosa published in Nature MedicineGlobeNewsWire • 07/25/23
COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, NeuropsychopharmacologyGlobeNewsWire • 07/17/23
Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybinGlobeNewsWire • 07/13/23
American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic TherapiesGlobeNewsWire • 07/06/23
COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules CapitalGlobeNewsWire • 07/05/23
TOMS Shoes founder is pledging $100 million for psychedelic research – Here's why he's doing it.Market Watch • 06/21/23
5 of Cathie Wood's Sizzling ARK Investment Stocks Are Buy Rated and Trading Under $1024/7 Wall Street • 06/17/23
COMPASS Pathways to participate in upcoming Cantor Fitzgerald and HC Wainwright investor conferencesGlobeNewsWire • 06/16/23
COMPASS Pathways' Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation OfficerGlobeNewsWire • 05/31/23
Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 studyPRNewsWire • 05/30/23
Compass shares jump as study shows psychedelic-based drug improved depression in cancer patientsMarket Watch • 05/26/23
Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023GlobeNewsWire • 05/26/23